Skip to content Skip to sidebar Skip to footer
Subscribe Now
Biopharma Deal Terminations Top 20 2020
TOP 20
Top 20 Biopharma Deal Terminations of 2020 Based on Total Deal Value
The biopharma industry saw numerous deal terminations in 2020. Clinical and regulatory results- change in control limitations- and strategic reprioritizations were among the most common reasons for deal termination. Sanofi and Hanmi's agreement in 2015 ranked first under which Hanmi regained WW rights to its protein/peptide discovery technology- lapscovery. The second position goes to the…
February 11, 20210Comments
Viewpoints_Andreas Harstrick
VIEWPOINTS
PharmaShots Interview: Affimed’s Andreas Harstrick Shares Insight on AFM13 and its Data Presented at ASH 2020
In an interview with PharmaShots, Dr. Andreas Harstrick, Chief Medical Officer at Affimed shared his views on updated clinical data related to their lead innate cell engager AFM13 at the virtual 62nd American Society of Hematology (ASH) annual meeting. Shots: The study showed an ORR of 42% (6/14 patients) and demonstrated clinical activity in two…
February 10, 20210Comments
Viewpoints_Duncan Short
VIEWPOINTS
PharmaShots Interview: ViiV Healthcare’s Duncan Short Shares Insight on PROgress Study Demonstrating that Pre-Visit Survey Can Improve HIV Care
In a recent interview with PharmaShots, Duncan Short, Ph.D., Director of Global Implementation Science at ViiV Healthcare shared his views on the findings of a new study demonstrating how the inclusion of a brief survey focused on patient-reported outcomes (PROs) during doctor's appointments can improve HIV care. Shots: In the study, people living with HIV were provided…
February 8, 20210Comments
Viewpoints_Edouard Gasser
VIEWPOINTS
PharmaShots Interview: Tilak Healthcare’s Edouard Gasser Shares Insights on OdySight
In a recent interview with PharmaShots, Edouard Gasser, CEO of Tilak Healthcare shared his views on OdySight, which is the first medical game to monitor eyesight for patients with chronic eye diseases. Shots: OdySight is a free mobile game and medical-grade application used to remotely monitor patients suffering from chronic maculopathies such as AMD, macular edema, and diabetic retinopathy…
February 4, 20210Comments
Viewpoints_Laura Yecies
VIEWPOINTS
PharmaShots Interview: BoneHealth Technologies’ Laura Yecies Shares Insights on OsteoBoost Vibration Belt
In a recent interview with PharmaShots, Laura Yecies, CEO of BoneHealth Technologies shared her views on OsteoBoost Vibration Belt that has been granted 'Breakthrough Device' designation by the US FDA Shots: OsteoBoost receives the US FDA's BDD to reduce the risk of osteoporosis. It uses vibration technology that delivers mechanical stimulation to the hips & spine at…
February 2, 20210Comments
Viewpoint_Patricia_Mae_Doykos
VIEWPOINTS
PharmaShots Interview: BMS Foundation’s Patricia Mae Doykos Shares Insights on COVID Advocacy Exchange
In a recent interview with PharmaShots, Patricia Mae Doykos, Lead, Health Equity Initiative, and Director, BMS Foundation at Bristol Myers Squibb shared her views on the promotion of health equity and improvement in health outcomes of populations disproportionately affected by serious diseases and conditions. Shots: CAE is a virtual platform that convenes advocacy groups, patients, and industry to…
January 27, 20210Comments
Viewpoint_Dr. Michael_Shepard_2021
VIEWPOINTS
PharmaShots Interview: Enosi LifeSciences’ Dr. H. Michael Shepard Shares Insights on TNF-Inhibiting Molecules
In a recent interview with PharmaShots, Dr. H. Michael Shepard CEO and Co-Founder of Enosi shared his views on the announcement that Enosi Life Sciences has filed a patent for three of its TNF-inhibiting molecules: EN1001 for autoimmune disease, along with EN2001 and EN3001 for autoimmune disease and cancer. Shots: Enosi will offer use in multiple diseases and…
January 27, 20210Comments